As a companion diagnostic, Oncomine will be used to identify patients eligible for treatment with Servier’s Voranigo.

This trial investigated the potential of Nanoscope Therapeutics' MCO-010 to restore vision in patients with retinitis ...

A stake by France-owned Bpifrance and promise of local job retention have allayed political backlash over the sale of ...

Arcutis Canada, has received Health Canada's approval for ZORYVE to treat seborrheic dermatitis in patients aged nine years ...

In an exclusive interview, the CEO of ImmunoPrecise Antibodies described the benefits of rabbit monoclonal antibodies in ...

A partial hold was placed on the trial after results showed variance between squamous and non-squamous NSCLC patient ...

FibroBiologics has entered a master services agreement with Charles River Laboratories to develop and manufacture cell-based ...

Astellas Pharma has received approval from the FDA for VYLOY in conjunction with chemotherapy, for the treatment of advanced ...

While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.

An FDA AdCom in September recommended against full approval for Ocaliva by a 13-1 vote for the treatment of primary biliary ...

A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.